Search results
Showing 1551 to 1600 of 3030 results for all
Evidence-based recommendations on percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism. This involves using a special device to block the mouth of the left atrial appendage and stop the blood clot from getting into the bloodstream.
View recommendations for HTG222Show all sections
Sections for HTG222
Totally endoscopic robotically assisted coronary artery bypass grafting (HTG77)
Evidence-based recommendations on totally endoscopic robotically assisted coronary artery bypass grafting (TECAB). This involves using small, remote-controlled robotic arms to carry out the grafting procedure.
View recommendations for HTG77Show all sections
Sections for HTG77
Caris Molecular Intelligence for guiding cancer treatment (MIB120)
NICE has developed a medtech innovation briefing (MIB) on Caris Molecular Intelligence for guiding cancer treatment .
View a complete list of indicators currently being developed. Our indicators measure outcomes that reflect the quality of care or processes.
Evidence-based recommendations on the EOS 2D/3D imaging system for producing 2D and 3D images of the skeleton.
Diabetes: blood pressure (without moderate or severe frailty) (IND249)
This indicator covers the percentage of patients with diabetes on the register, aged 79 years and under without moderate or severe frailty, in whom the last blood pressure reading (measured in the preceding 12 months) is less than 135/85 mmHg if using ambulatory or home monitoring, or less than 140/90 mmHg if measured in clinic. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM233
Guidance on the use of paclitaxel in the treatment of ovarian cancer (TA55)
Evidence-based recommendations on paclitaxel for treating ovarian cancer in adults.
Sodium zirconium cyclosilicate for treating hyperkalaemia (TA1148)
Evidence-based recommendations on sodium zirconium cyclosilicate (Lokelma) for treating hyperkalaemia in adults.
Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderately to severely active ulcerative colitis in adults.
Pazopanib for the first-line treatment of advanced renal cell carcinoma (TA215)
Evidence-based recommendations on pazopanib (Votrient) for previously untreated advanced renal cell carcinoma in adults.
Evidence-based recommendations on futibatinib (Lytgobi) for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.
Show all sections
Lenalidomide with rituximab for previously treated follicular lymphoma (TA627)
Evidence-based recommendations on lenalidomide (Revlimid) with rituximab for previously treated follicular lymphoma (grade 1 to 3A) in adults.
Evidence-based recommendations on durvalumab (Imfinzi) for treating limited-stage small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy in adults.
Show all sections
Evidence-based recommendations on brexucabtagene autoleucel (Tecartus) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over.
Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)
Evidence-based recommendations on mannitol dry powder for inhalation (Bronchitol) for treating cystic fibrosis in adults
Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy in adults.
Evidence-based recommendations on belumosudil (Rezurock) for chronic graft-versus-host disease in people 12 years and over after 2 or more systemic treatments.
NICE has developed a medtech innovation briefing (MIB) on OrganOx metra for liver transplant .
ViewSite Brain Access System (VBAS) for the surgical management of deep brain lesions (MIB295)
NICE has developed a medtech innovation briefing (MIB) on ViewSite Brain Access System (VBAS) for the surgical management of deep brain lesions .
Arctic Sun 5000 for therapeutic hypothermia after cardiac arrest (MIB112)
NICE has developed a medtech innovation briefing (MIB) on Arctic Sun 5000 for therapeutic hypothermia after cardiac arrest .
Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis (MIB93)
NICE has developed a medtech innovation briefing (MIB) on the Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis .
Evidence standards framework for digital health technologies (ECD7)
This document describes an evidence standards framework (ESF) for digital health technologies (DHTs). It was developed by NICE between June 2018 and February 2019 in collaboration with NHS England, Public Health England and MedCity. The work was commissioned by NHS England
Evidence-based recommendations on relugolix–estradiol–norethisterone acetate (Ryeqo) for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.
Acalabrutinib for treating chronic lymphocytic leukaemia (TA689)
Evidence-based recommendations on acalabrutinib (Calquence) for treating chronic lymphocytic leukaemia in adults.
Upadacitinib for treating moderate rheumatoid arthritis (TA744)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderate active rheumatoid arthritis in adults.
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma (TA874)
Evidence-based recommendations on polatuzumab vedotin (Polivy) with rituximab, cyclophosphamide, doxorubicin and prednisolone for untreated diffuse large B-cell lymphoma in adults.
Details of the business expenses incurred by the board and senior management team in delivery of their duties.
This guide describes the process NICE uses to develop NICE quality standards
HTG EdgeSeq ALKPlus Assay EU for ALK status testing in non-small-cell lung cancer (MIB128)
NICE has developed a medtech innovation briefing (MIB) on HTG EdgeSeq ALKPlus Assay EU for ALK status testing in non-small-cell lung cancer .
Evidence-based recommendations on ivosidenib (Tibsovo) for treating locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation in adults after 1 or more systemic treatments.
Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)
Evidence-based recommendations on tolvaptan (Jinarc) for treating autosomal dominant polycystic kidney disease in adults.
Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)
Evidence-based recommendations on nalmefene (Selincro) for reducing alcohol consumption in adults with alcohol dependence.
Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis (TA590)
Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for treating recurrent non-infectious uveitis in adults.
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts (TA399)
Evidence-based recommendations on azacitidine (Vidaza) for treating acute myeloid leukaemia with more than 30% bone marrow blasts.
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)
Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and for preventing a further deep vein thrombosis or pulmonary embolism in adults.
Evidence-based recommendations on vemurafenib (Zelboraf) for treating advanced BRAF V600-positive malignant melanoma in adults.
NICE has developed a Medtech Innovation Briefing (MIB) on the Oncentra Prostate v4.x ultrasound-guided real-time HDR brachytherapy in men with localised
Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)
Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia in adults.
Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]
In development Reference number: GID-TA10832 Expected publication date: TBC
NICE has developed a medtech innovation briefing (MIB) on AI technologies for detecting diabetic retinopathy .
eazyplex SuperBug kits for detecting carbapenemase-producing organisms (MIB94)
NICE has developed a medtech innovation briefing (MIB) on eazyplex SuperBug kits for detecting carbapenemase-producing organisms .
This guideline covers the diagnosis and management of gout. It includes recommendations on diagnosing gout, managing flares, long-term management of gout and referral to specialist services.
Magseed for locating impalpable breast cancer lesions (MIB236)
NICE has developed a medtech innovation briefing (MIB) on Magseed for locating impalpable breast cancer lesions .
Actim Pancreatitis for diagnosing acute pancreatitis (MIB218)
NICE has developed a medtech innovation briefing (MIB) on Actim Pancreatitis for diagnosing acute pancreatitis .
NICE has developed a medtech innovation briefing (MIB) on the ATEC breast biopsy system
Irreversible electroporation for treating liver metastases (HTG304)
Evidence-based recommendations on irreversible electroporation for the treatment of liver metastases. This involves using very short electrical field pulses delivered over several minutes to destroy the tumour and a small surrounding tissue margin.
View recommendations for HTG304Show all sections
Sections for HTG304
Evidence-based recommendations on percutaneous laser therapy for fetal tumours. This involves inserting a needle through the mother's abdomen to the tumour and using laser energy to shrink it.
View recommendations for HTG118Show all sections
Sections for HTG118
Insertion of pleuro–amniotic shunt for fetal pleural effusion (HTG123)
Evidence-based recommendations on inserting a pleuro-amniotic shunt to drain pleural effusions in a fetus during pregnancy. This involves inserting a drainage tube through the fetal chest wall into the pleural space, allowing fluid to drain into the amniotic cavity.
View recommendations for HTG123Show all sections
Sections for HTG123
Evidence-based recommendations on melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver. This involves diverting the blood flow from the liver to the rest of the body while the drug is delivered directly into the liver.
View recommendations for HTG575Show all sections
Norucholic acid for treating primary sclerosing cholangitis [ID6583]
Awaiting development Reference number: GID-TA11782 Expected publication date: 29 April 2027